IBI-Ag develops next-generation bioinsecticides using proprietary protein and AI-driven design, delivering precision, safety, and sustainability to modern agriculture.
Insect pests cause hundreds of billions in crop losses every year, and the industry’s answers, whether synthetic chemicals or early-generation biopesticides, have fallen short on safety, sustainability, resistance, and performance. The market is ready for something better.
IBI-Ag develops two generations of precision bioinsecticides, proven today, and engineered for tomorrow.
Our first-generation products are nanobody-based bioinsecticides, single domain antibodies developed in vivo, with a validated proprietary target library and demonstrated efficacy against key insect pest species.
Our second generation takes this foundation further, leveraging state-of-the-art computational AI and our proprietary IP to design de novo bioinsecticide proteins, faster, broader, and against targets previously out of reach.
IBI-Ag operates two complementary discovery engines combining the proven
precision of single domain antibodies engineering with the speed and versatility
of AI-driven de novo protein design.
Our disruptive IP is based on insect targets validated in vivo with an extensive library of single domain antibodies. Our de novo design capabilities draw from this unique proprietary foundation to generate protein binders never seen before.
In early 2026, we completed the world’s first proof-of-concept for an AI-driven de novo bioinsecticide platform — designing and validating novel proteins against key agricultural pests in just 4 months.
New Mode of Action (MoA) bottom up – our unique approach is starting by choosing a new MoA and building the new product to accommodate it.
Selective by design – Our proteins are engineered to target specific insect species, minimizing off-target effects on non-target organisms, pollinators, and ecosystems.
Safe for people and the planet – Based on naturally derived proteins with no synthetic chemical residues. Our active ingredients present minimal risk to farmers, consumers, and the environment.
From target to candidate in 4 months – Our AI De Novo design platform compresses development timelines that previously required a year or more into a fraction of the time.
Iterative experimental testing that feeds data back into the computational pipeline, continuously improving design accuracy
